Cite

HARVARD Citation

    Hézode, C. et al. (2017). Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver international. pp. 1314-1324. [Online]. 
  
Back to record